| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |